Ajer Jeffrey Robert's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Oct 28, 2021
- Accession no.
- 0001567619-21-018936
- Filed
- Oct 28, 2021
- Trade date
- Apr 30-Oct 26, 2021
- Filing delay
- 181 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $201.6K. It was filed 181 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ajer Jeffrey RobertCIK 0001557533 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 30, 2021 | Common Stock | AGrant or awardAcquired | +342 | $62.41 | +$21,344.22 | 58,592 | Direct | |
| Oct 26, 2021 | Common Stock | SSaleDisposed | −2,739 | $73.60 | −$201,590.4 | 55,853 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.